These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22841478)

  • 1. Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (Inactivated) (JEBIK(®)V) in children.
    Okada K; Iwasa T; Namazue J; Akechi M; Ueda S;
    Vaccine; 2012 Sep; 30(41):5967-72. PubMed ID: 22841478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated).
    Kikukawa A; Gomi Y; Akechi M; Onishi T; Manabe S; Namazue J; Fuke I; Ishikawa T; Okuno Y; Ueda S
    Vaccine; 2012 Mar; 30(13):2329-35. PubMed ID: 22306856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
    Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
    Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
    Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.
    Woolpert T; Staples JE; Faix DJ; Nett RJ; Kosoy OI; Biggerstaff BJ; Johnson BW; Sracic M; Fischer M
    Vaccine; 2012 Apr; 30(20):3090-6. PubMed ID: 22406277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study.
    Schuller E; Klade CS; Wölfl G; Kaltenböck A; Dewasthaly S; Tauber E
    Vaccine; 2009 Mar; 27(15):2188-93. PubMed ID: 19200452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is a booster dose necessary in children after immunization with live attenuated Japanese encephalitis vaccine?
    Choi UY; Lee SY; Kim KH; Kim DS; Choi KM; Cha SH; Kang JH
    J Trop Pediatr; 2013 Oct; 59(5):423-5. PubMed ID: 23764540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III clinical trials comparing the immunogenicity and safety of the vero cell-derived Japanese encephalitis vaccine Encevac with those of mouse brain-derived vaccine by using the Beijing-1 strain.
    Miyazaki C; Okada K; Ozaki T; Hirose M; Iribe K; Yokote H; Ishikawa Y; Togashi T; Ueda K
    Clin Vaccine Immunol; 2014 Feb; 21(2):188-95. PubMed ID: 24334689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Sabchareon A; Pancharoen C; Bouckenooghe A; Gailhardou S; Boaz M; Feroldi E
    Pediatr Infect Dis J; 2010 Dec; 29(12):1111-7. PubMed ID: 20856164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
    Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
    Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.
    Tauber E; Kollaritsch H; von Sonnenburg F; Lademann M; Jilma B; Firbas C; Jelinek T; Beckett C; Knobloch J; McBride WJ; Schuller E; Kaltenböck A; Sun W; Lyons A
    J Infect Dis; 2008 Aug; 198(4):493-9. PubMed ID: 18588481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial.
    Tauber E; Kollaritsch H; Korinek M; Rendi-Wagner P; Jilma B; Firbas C; Schranz S; Jong E; Klingler A; Dewasthaly S; Klade CS
    Lancet; 2007 Dec; 370(9602):1847-53. PubMed ID: 18061060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.
    Cramer JP; Jelinek T; Paulke-Korinek M; Reisinger EC; Dieckmann S; Alberer M; Bühler S; Bosse D; Meyer S; Fragapane E; Costantini M; Pellegrini M; Lattanzi M; Dovali C
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 26994987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 May; 60(20):661-3. PubMed ID: 21617632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
    Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
    Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand.
    Chotpitayasunondh T; Sohn YM; Yoksan S; Min J; Ohrr H
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S195-203. PubMed ID: 22043776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.